Predict your next investment

Asset/Investment Management
adagecapital.com

See what CB Insights has to offer

Investments

72

Portfolio Exits

42

About Adage Capital Management

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%.The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years.

Adage Capital Management Headquarter Location

200 Clarendon Street

Boston, Massachusetts, 02116,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Adage Capital Management

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Adage Capital Management in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Research containing Adage Capital Management

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Adage Capital Management in 2 CB Insights research briefs, most recently on May 27, 2021.

Latest Adage Capital Management News

Beckley Psytech Closes $80M Series B Funding

Aug 16, 2021

Beckley Psytech , an Oxford, England-based private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, closed an $80m Series B financing. The round was led by Integrated, with participation from Prime Movers Labs, Adage Capital Management, Palo Santo; Delphi VC; Leafy Tunnel; Negev Capital; and existing investor Bicycle Day Ventures. The company intends to use the funds to complete the ongoing Phase 1b trial with low-dose psilocybin in patients suffering from SUNHA, a rare and debilitating headache condition estimated to affect 45,000 people in the US and Europe, and to initiate a Phase 1 dose-ranging study on a novel formulation of intranasal 5-MeO-DMT before starting a Phase 2 trial in Treatment Resistant Depression, and expand its pipeline with new, unique and proprietary psychedelic compounds. Led by Cosmo Feilding Mellen, CEO, Beckley Psytech is a clinical stage company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Its vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world, suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment resistant depression and other profoundly debilitating conditions. FinSMEs 16/08/2021

Adage Capital Management Investments

72 Investments

Adage Capital Management has made 72 investments. Their latest investment was in Beckley Psytech as part of their Series B on August 8, 2021.

CBI Logo

Adage Capital Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/16/2021

Series B

Beckley Psytech

$80M

Yes

Bicycle Day Ventures, Delphi Ventures, Integrated, Leafy Tunnel, Negev Capital, Palo Santo, and Prime Movers Lab

4

8/5/2021

Series B

PepGen

$112.5M

Yes

CureDuchenne Ventures, Deerfield Management, Gray's Creek Capital Partners, Laurion Capital Management, Oxford Sciences Innovation, RA Capital Management, Samsara BioCapital, Tudor Investment Corporation, and Viking Global Investors

5

7/30/2021

Series H

goPuff

$1,000M

Yes

Atreides Management, Blackstone, Eldridge, Fidelity Investments, Guggenheim Investments, Hedosophia, MSD Partners, and SoftBank Group

6

6/24/2021

Series F

Subscribe to see more

$99M

Subscribe to see more

10

6/9/2021

Series D - IV

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/16/2021

8/5/2021

7/30/2021

6/24/2021

6/9/2021

Round

Series B

Series B

Series H

Series F

Series D - IV

Company

Beckley Psytech

PepGen

goPuff

Subscribe to see more

Subscribe to see more

Amount

$80M

$112.5M

$1,000M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Bicycle Day Ventures, Delphi Ventures, Integrated, Leafy Tunnel, Negev Capital, Palo Santo, and Prime Movers Lab

CureDuchenne Ventures, Deerfield Management, Gray's Creek Capital Partners, Laurion Capital Management, Oxford Sciences Innovation, RA Capital Management, Samsara BioCapital, Tudor Investment Corporation, and Viking Global Investors

Atreides Management, Blackstone, Eldridge, Fidelity Investments, Guggenheim Investments, Hedosophia, MSD Partners, and SoftBank Group

Sources

4

5

6

10

10

Adage Capital Management Portfolio Exits

42 Portfolio Exits

Adage Capital Management has 42 portfolio exits. Their latest portfolio exit was Caribou Biosciences on July 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/23/2021

IPO

$991

2

7/16/2021

IPO

$991

2

6/18/2021

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

7/23/2021

7/16/2021

6/18/2021

00/00/0000

00/00/0000

Exit

IPO

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

Adage Capital Management Team

1 Team Member

Adage Capital Management has 1 team member, including current Managing Director, Phill Gross.

Name

Work History

Title

Status

Phill Gross

Managing Director

Current

Name

Phill Gross

Work History

Title

Managing Director

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.